226 related articles for article (PubMed ID: 2337896)
21. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin.
Tsuruo T; Iida H; Yamashiro M; Tsukagoshi S; Sakurai Y
Biochem Pharmacol; 1982 Oct; 31(19):3138-40. PubMed ID: 7150340
[TBL] [Abstract][Full Text] [Related]
22. Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.
Wilkoff LJ; Dulmadge DA; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1989; 23(3):145-50. PubMed ID: 2924372
[TBL] [Abstract][Full Text] [Related]
23. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52.
Shinoda H; Inaba M; Tsuruo T
Cancer Res; 1989 Apr; 49(7):1722-6. PubMed ID: 2924316
[TBL] [Abstract][Full Text] [Related]
24. Antitumour effects and pharmacokinetics of combination of vinblastine with a staurosporine derivative, NA-382, in P388/ADR-bearing mice.
Miyamoto K; Takeda K; Koga K; Ohshima T; Wakusawa S
J Pharm Pharmacol; 1995 Jun; 47(6):524-9. PubMed ID: 7674138
[TBL] [Abstract][Full Text] [Related]
25. Circumvention of adriamycin resistance: effect of 2-methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells.
Parekh HK; Mansuri-Torshizi H; Srivastava TS; Chitnis MP
Cancer Lett; 1992 Jan; 61(2):147-56. PubMed ID: 1730138
[TBL] [Abstract][Full Text] [Related]
26. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells by dipyrone.
Chitnis MP; Kamath NS
Oncology; 1987; 44(1):47-50. PubMed ID: 3561929
[TBL] [Abstract][Full Text] [Related]
27. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
28. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
Inaba M; Maruyama E
Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
[TBL] [Abstract][Full Text] [Related]
29. Reversal of multidrug resistance by an immunosuppressive agent FK-506.
Naito M; Oh-hara T; Yamazaki A; Danki T; Tsuruo T
Cancer Chemother Pharmacol; 1992; 29(3):195-200. PubMed ID: 1370765
[TBL] [Abstract][Full Text] [Related]
30. Effects of isoquinolinesulphonamide compounds on multidrug-resistant P388 cells.
Nakamura S; Wakusawa S; Tajima K; Miyamoto K; Hagiwara M; Hidaka H
J Pharm Pharmacol; 1993 Apr; 45(4):268-73. PubMed ID: 8098366
[TBL] [Abstract][Full Text] [Related]
31. Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro.
Kiue A; Sano T; Naito A; Inada H; Suzuki K; Okumura M; Kikuchi J; Sato S; Takano H; Kohno K
Jpn J Cancer Res; 1990 Oct; 81(10):1057-64. PubMed ID: 1977728
[TBL] [Abstract][Full Text] [Related]
32. Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
Sato W; Fukazawa N; Nakanishi O; Baba M; Suzuki T; Yano O; Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):271-7. PubMed ID: 7828268
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D
Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
[TBL] [Abstract][Full Text] [Related]
34. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide.
Nakashima E; Matsushita R; Negishi H; Nomura M; Harada S; Yamamoto H; Miyamoto K; Ichimura F
J Pharm Sci; 1995 Oct; 84(10):1205-9. PubMed ID: 8801335
[TBL] [Abstract][Full Text] [Related]
35. Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42 degrees C).
Juvekar AS; Chitnis MP
Neoplasma; 1991; 38(2):207-11. PubMed ID: 2041579
[TBL] [Abstract][Full Text] [Related]
36. Modulation of in vitro chemosensitivity by extracellular Ca++ in adriamycin sensitive and resistant P388 leukemic cells.
Adwankar MK; Chitnis MP
Neoplasma; 1990; 37(1):31-6. PubMed ID: 2320178
[TBL] [Abstract][Full Text] [Related]
37. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.
Ramu A; Fuks Z; Gatt S; Glaubiger D
Cancer Res; 1984 Jan; 44(1):144-8. PubMed ID: 6690032
[TBL] [Abstract][Full Text] [Related]
38. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Satyamoorthy K; Deshpande SS; Chitnis MP
Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
[TBL] [Abstract][Full Text] [Related]
39. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
40. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.
Inaba M; Kobayashi H; Sakurai Y; Johnson RK
Cancer Res; 1979 Jun; 39(6 Pt 1):2200-3. PubMed ID: 445418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
